Elena Jarrín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elena Jarrín has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
A. Almendral
Servicio de Oftalmología, IRYCIS, Hospital Ramón y Cajal, Madrid, España
1 shared publicationAntonio Mendivil
1 shared publicationC. Cabarga-Nozal
Servicio de Oftalmología, IRYCIS, Hospital Ramón y Cajal, Madrid, España
1 shared publicationDiego Ruiz-Casas
1 shared publicationF.J. Muñoz-Negrete
Servicio de Oftalmología, IRYCIS, Hospital Ramón y Cajal, Madrid, España
1 shared publication- Francisco Arnalich-Montiel
Department of Ophthalmology, Hospital Universitario Ramon y Cajal, Madrid, Spain
1 shared publication
Latest Publications
- 2 January 2017
- Published by Taylor & Francis in Strabismus
- Vol. 25 (1) , 1-4
Clinical Characteristics, Treatment, and Outcome of Trochleitis
Background and purpose: To study the clinical characteristics, treatment options, and outcome of patients with trochleitis in our population. Methods: Retrospective review of 59 patients diagnosed with trochleitis in the Ramon y Cajal Hospital Emergency Service between 2003 and 2010. Demographic data and trochleitis features were described. The relationship between outcome and treatment options was analyzed by SPSS. Results: The estimated prevalence rate of trochleitis in our area was 12 per 100,000. The average age of patients was 43±18 years. The majority of cases were women (86%). One case was bilateral. Patients’ chief complaints were continuous pain (66%), pain only with ocular movements (25%), or pain only with palpation (8%). Ocular movement limitations were presented in 14%. Diplopia was observed in 12%, and 19% complained of headache. Oral non-steroidal anti-inflammatory drugs (NSAIDs) were the first option for treatment in 85% of cases, associated with oral steroids in 8% of patients. Oral steroids were the first and only option for treatment in 3%. Symptoms completely resolved in 80%, with the worst responses seen in cases with motility disturbances. Peritrochlear triamcinolone acetonide was injected in 14% of cases, achieving a good response in 62%. Conclusions: The prevalence of trochleitis in our area is low, and this pathology is more frequent in females. Oral NSAIDs are efficient to resolve isolated pain, but the response is partial if diplopia or motility limitations are associated. Some non-responders achieved good results with peritrochlear triamcinolone. Successful management provides a good prognosis for most patients.
- 2 January 2017
- Published by Taylor & Francis in Strabismus
- Vol. 25 (1) , 1-4
Clinical Characteristics, Treatment, and Outcome of Trochleitis
Background and purpose: To study the clinical characteristics, treatment options, and outcome of patients with trochleitis in our population. Methods: Retrospective review of 59 patients diagnosed with trochleitis in the Ramon y Cajal Hospital Emergency Service between 2003 and 2010. Demographic data and trochleitis features were described. The relationship between outcome and treatment options was analyzed by SPSS. Results: The estimated prevalence rate of trochleitis in our area was 12 per 100,000. The average age of patients was 43±18 years. The majority of cases were women (86%). One case was bilateral. Patients’ chief complaints were continuous pain (66%), pain only with ocular movements (25%), or pain only with palpation (8%). Ocular movement limitations were presented in 14%. Diplopia was observed in 12%, and 19% complained of headache. Oral non-steroidal anti-inflammatory drugs (NSAIDs) were the first option for treatment in 85% of cases, associated with oral steroids in 8% of patients. Oral steroids were the first and only option for treatment in 3%. Symptoms completely resolved in 80%, with the worst responses seen in cases with motility disturbances. Peritrochlear triamcinolone acetonide was injected in 14% of cases, achieving a good response in 62%. Conclusions: The prevalence of trochleitis in our area is low, and this pathology is more frequent in females. Oral NSAIDs are efficient to resolve isolated pain, but the response is partial if diplopia or motility limitations are associated. Some non-responders achieved good results with peritrochlear triamcinolone. Successful management provides a good prognosis for most patients.
- 1 August 2015
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 90 (8) , 379-381
Diágnóstico del lenticono en el síndrome de Alport: cálculo del ángulo apical de la cápsula anterior del cristalino mediante imágenes Scheimpflug
- 1 August 2015
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 90 (8) , 379-381
Diágnóstico del lenticono en el síndrome de Alport: cálculo del ángulo apical de la cápsula anterior del cristalino mediante imágenes Scheimpflug
- 1 September 2014
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 89 (9) , 352-360
Iridotomía periférica láser frente a facoemulsificación en el cierre angular primario: estudio comparativo prospectivo
- 1 September 2014
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 89 (9) , 352-360
Iridotomía periférica láser frente a facoemulsificación en el cierre angular primario: estudio comparativo prospectivo
- 1 February 2012
- Published by Wolters Kluwer Health in Cornea
- Vol. 31 (2) , 188-190
Efficacy of Bevacizumab Against Interface Neovascularization After Deep Anterior Lamellar Keratoplasty
We report a case of neovascularization at the interface after a deep anterior lamellar keratoplasty and its regression after a single bevacizumab injection. Case report. We present a case of neovascularization and bleeding at the interface 2 days after a deep anterior lamellar keratoplasty for herpetic disease that was completely reversed by a single injection of bevacizumab at the interface. Corneal neovascularization is a typical sign of herpetic disease and one of the most important risk factors that can contribute to corneal graft failure. Close follow-up of patients at risk is necessary to detect and treat this complication as soon as possible to achieve a good outcome. Bevacizumab seems to be a successful and safe therapeutic option.
- 1 February 2012
- Published by Wolters Kluwer Health in Cornea
- Vol. 31 (2) , 188-190
Efficacy of Bevacizumab Against Interface Neovascularization After Deep Anterior Lamellar Keratoplasty
We report a case of neovascularization at the interface after a deep anterior lamellar keratoplasty and its regression after a single bevacizumab injection. Case report. We present a case of neovascularization and bleeding at the interface 2 days after a deep anterior lamellar keratoplasty for herpetic disease that was completely reversed by a single injection of bevacizumab at the interface. Corneal neovascularization is a typical sign of herpetic disease and one of the most important risk factors that can contribute to corneal graft failure. Close follow-up of patients at risk is necessary to detect and treat this complication as soon as possible to achieve a good outcome. Bevacizumab seems to be a successful and safe therapeutic option.